Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | GFER | P55789 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.39 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | YWHAG | P61981 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20231853 | 1.00 | MAPT (0.54) | MAPTALDH1A1GFERLMNAMAPK1 | |
| SCHEMBL24735339 | 0.91 | ALDH1A1 (0.48) | MAPTALDH1A1GFERLMNAMAPK1 | |
| SCHEMBL24735237 | 0.91 | ALDH1A1 (0.48) | MAPTALDH1A1GFERLMNAMAPK1 | |
| SCHEMBL24735594 | 0.91 | ALDH1A1 (0.48) | MAPTALDH1A1GFERLMNAMAPK1 | |
| SCHEMBL23823282 | 0.86 | ALDH1A1 (0.49) | MAPTALDH1A1GFERLMNAMAPK1 | |
| SCHEMBL24735187 | 0.84 | ALDH1A1 (0.49) | MAPTALDH1A1GFERLMNAMAPK1 | |
| SCHEMBL9983818 | 0.83 | ALDH1A1 (0.46) | MAPTALDH1A1GFERLMNAMAPK1 | |
| SCHEMBL854063 | 0.83 | MAPT (0.58) | MAPTALDH1A1GFERLMNAMAPK1 | |
| SCHEMBL29507892 | 0.83 | MAPT (0.58) | MAPTALDH1A1GFERLMNAMAPK1 | |
| SCHEMBL25845423 | 0.82 | ALDH1A1 (0.51) | MAPTALDH1A1GFERLMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116917280-B | Tetrahydronaphthalene compound, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| WO-2025228947-A1 | BIFUNCTIONAL COMPOUNDS CAPABLE OF INDUCING DEGRADATION OF POLO-LIKE KINASE1 | CROSSFIRE ONCOLOGY B.V. (NL) | 2025-11-06 | — | — | WO | disclosed |
| EP-4561999-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | Abbvie Operations Singapore Pte. Ltd. (SG) | 2025-06-04 | — | — | EP | disclosed |
| CN-115003295-B | Novel chroman derivatives having estrogen receptor degrading activity and uses thereof | 冰洲石生物科技公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-119923391-A | Targeted protein degradation of PARP14 for use in therapy | 艾伯维新加坡运营私人有限公司 | 2025-05-02 | — | — | CN | disclosed |
| US-20250099596-A1 | TETRAHYDRONAPHTHALENE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2025-03-27 | — | — | US | disclosed |
| EP-4317146-A1 | TETRAHYDRONAPHTHALENE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2024-02-07 | — | — | EP | disclosed |
| WO-2024026081-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | RIBON THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| CN-117229286-A | Aromatic compound, preparation method thereof and application thereof in preparation of estrogen receptor degradation agent | 海创药业股份有限公司 | 2023-12-15 | — | — | CN | disclosed |
| CN-116917280-A | Tetrahydronaphthalene compound, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-115611909-A | Tetrahydronaphthalene compound, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2023-01-17 | — | — | CN | disclosed |
| WO-2022206737-A1 | TETRAHYDRONAPHTHALENE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | 江苏恒瑞医药股份有限公司 | 2022-10-06 | — | — | WO | disclosed |
| CN-115003295-A | Novel chroman derivatives having estrogen receptor degrading activity and uses thereof | 冰洲石生物科技公司 | 2022-09-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099596-A1 | TETRAHYDRONAPHTHALENE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | CYP51A1, CYP46A1, HSD17B11 | MAPT 2176/4885ALDH1A1 843/4885GFER 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.